Cost modeling for monoclonal antibody manufacturing

Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering; in conjunction with the Leaders for Global Operations Program at MIT, 2011. === Cataloged from PDF version of thesis. === Includes...

Full description

Bibliographic Details
Main Author: Simpson, Christina M. (Christina Margaret)
Other Authors: Charles L. Cooney and Roy Welsch.
Format: Others
Language:English
Published: Massachusetts Institute of Technology 2011
Subjects:
Online Access:http://hdl.handle.net/1721.1/66050
id ndltd-MIT-oai-dspace.mit.edu-1721.1-66050
record_format oai_dc
spelling ndltd-MIT-oai-dspace.mit.edu-1721.1-660502019-05-02T16:27:10Z Cost modeling for monoclonal antibody manufacturing Simpson, Christina M. (Christina Margaret) Charles L. Cooney and Roy Welsch. Leaders for Global Operations Program. Sloan School of Management. Massachusetts Institute of Technology. Dept. of Mechanical Engineering. Leaders for Global Operations Program. Sloan School of Management. Mechanical Engineering. Leaders for Global Operations Program. Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering; in conjunction with the Leaders for Global Operations Program at MIT, 2011. Cataloged from PDF version of thesis. Includes bibliographical references (p. 75-76). The Novartis BioPharmOps division is responsible for manufacturing large molecule products, including monoclonal antibodies, for late stage clinical trials and commercial sales. The BioPharmOps site in Huningue, France is expanding their product line but is also trying to reduce costs; cost pressures are increasing as biotech products become a larger part of Novartis' pipeline. The site uses a standard cost method to calculate their product costs. However, when using standard costs it can be time-consuming to extrapolate and predict costs when inputs and assumptions (such as product mix or process parameters) are changed. This project describes development of a model that allows the factory to quickly and easily simulate new product mixes and process flows. This model provides the site with a different view of their costs that will help them understand their cost drivers more completely and thereby help enable strategic decision-making at the site. A model of this type can be used to provide unexpected insights but the data in it are not meant to stand alone. By using results from a cost model like this along with operational metrics like throughput time or changeover time, a site should be able to quickly predict the cost impact of process changes or changes in the production plan. by Christina M. Simpson. S.M. M.B.A. 2011-09-27T18:36:53Z 2011-09-27T18:36:53Z 2011 2011 Thesis http://hdl.handle.net/1721.1/66050 752309922 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 76 p. application/pdf Massachusetts Institute of Technology
collection NDLTD
language English
format Others
sources NDLTD
topic Sloan School of Management.
Mechanical Engineering.
Leaders for Global Operations Program.
spellingShingle Sloan School of Management.
Mechanical Engineering.
Leaders for Global Operations Program.
Simpson, Christina M. (Christina Margaret)
Cost modeling for monoclonal antibody manufacturing
description Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering; in conjunction with the Leaders for Global Operations Program at MIT, 2011. === Cataloged from PDF version of thesis. === Includes bibliographical references (p. 75-76). === The Novartis BioPharmOps division is responsible for manufacturing large molecule products, including monoclonal antibodies, for late stage clinical trials and commercial sales. The BioPharmOps site in Huningue, France is expanding their product line but is also trying to reduce costs; cost pressures are increasing as biotech products become a larger part of Novartis' pipeline. The site uses a standard cost method to calculate their product costs. However, when using standard costs it can be time-consuming to extrapolate and predict costs when inputs and assumptions (such as product mix or process parameters) are changed. This project describes development of a model that allows the factory to quickly and easily simulate new product mixes and process flows. This model provides the site with a different view of their costs that will help them understand their cost drivers more completely and thereby help enable strategic decision-making at the site. A model of this type can be used to provide unexpected insights but the data in it are not meant to stand alone. By using results from a cost model like this along with operational metrics like throughput time or changeover time, a site should be able to quickly predict the cost impact of process changes or changes in the production plan. === by Christina M. Simpson. === S.M. === M.B.A.
author2 Charles L. Cooney and Roy Welsch.
author_facet Charles L. Cooney and Roy Welsch.
Simpson, Christina M. (Christina Margaret)
author Simpson, Christina M. (Christina Margaret)
author_sort Simpson, Christina M. (Christina Margaret)
title Cost modeling for monoclonal antibody manufacturing
title_short Cost modeling for monoclonal antibody manufacturing
title_full Cost modeling for monoclonal antibody manufacturing
title_fullStr Cost modeling for monoclonal antibody manufacturing
title_full_unstemmed Cost modeling for monoclonal antibody manufacturing
title_sort cost modeling for monoclonal antibody manufacturing
publisher Massachusetts Institute of Technology
publishDate 2011
url http://hdl.handle.net/1721.1/66050
work_keys_str_mv AT simpsonchristinamchristinamargaret costmodelingformonoclonalantibodymanufacturing
_version_ 1719040971916705792